Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CMV-specific T cells plus Keytruda for glioblastoma or grade 4 astrocytoma
ACTRN12623001126606Phase 2Suspended
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and allogeneic CMV-specific T cells in glioblastoma (GBM) and astrocytoma (5 arms), sponsored by QIMR Berghofer Medical Research Institute. Primary endpoints: Safety and Dose-limiting toxicities and maximum tolerated dose. Started May 2024; status: suspended.
02
Drugs
pembrolizumaballogeneic CMV-specific T cells
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on ACTRN12623001126606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001126606.